compound_name,gene_name_of_protein_target,target_or_activity_of_compoundzebularine,DNMT1,inhibitor of DNA methyltransferasesazacitidine,DNMT1,inhibitor of DNA methyltransferasenelarabine,POLA1,deoxyguanosine analog; inhibitor of DNA synthesismyricetin,,flavonoid antioxidantBRD-K64610608,,product of diversity oriented synthesis; screening hitML334 diastereomer,KEAP1;NFE2L2,inhibitor of KEAP1-NFE2L2 protein-protein interactionBRD-K09344309,,screening hitisonicotinohydroxamic acid,HDAC6,inhibitor of HDAC6QS-11,ARFGAP1,inhibitor of GTPase activating protein of ARF 1 (ARFGAP1)brivanib,FLT1;KDR,inhibitor of VEGFR 1/2BRD8958,EP300,inhibitor of E1A binding protein p300BRD-K34099515,,screening hitA-804598,P2RX7,inhibitor of purinergic receptor P2Xerismodegib,,screening hitabiraterone,CYP17A1,"inhibitor of 17 alpha-hydroxylase and C17,20 lyase"ifosfamide,,DNA alkylatortemozolomide,,DNA alkylatorBRD-A05715709,IDH1,putative inhibitor of IDH1 R132HBRD-K48477130,,screening hitCAY10594,PLD2,inhibitor of phospholipase D2WP1130,UCHL5;USP14;USP5;USP9X,"inhibitor of the deubiquitinase activity of USP9X, USP5, USP14, and UCH37"tamoxifen,ESR1;ESR2,modulator of estrogen receptorsimportazole,KPNB1,inhibitor of importinML006,S1PR3,agonist of sphingosine 1-phosphate receptor 3AM-580,RARA,agonist of retinoic acid receptor alphaCD-1530,RARG,agonist of retinoic acid receptor gammasilmitasertib,CSNK2A1;CSNK2A2,inhibitor of casein kinase 2PRL-3 inhibitor I,PTP4A3,inhibitor of phosphatase of regenerating liver-3 (PRL3)NPC-26,,"induces cell death through a non-apoptotic, mitochondrial-dependent mechanism"betulinic acid,,natural product; inhibitor of specificity protein 1 transcription factor in cellssalermide,SIRT1;SIRT2,inhibitor of sirtuin 1 and sirtuin 2BRD-M00053801,BCL2,inhibitor of BCL2AA-COCF3,FAAH;PLA2G4A;PLA2G4B;PLA2G4C;PLA2G4D,inhibitor of cytosolic phospholipase A2; inhibitor of fatty acid amide hydrolaseCI-976,ACAT1,inhibitor of acetyl-CoA acetyltransferase Ipifithrin-alpha,,inhibitor of p53-dependent signalingpurmorphamine,SMO,activator of smoothened receptorBIBR-1532,TERT,inhibitor of telomerase reverse transcriptaseniclosamide,STAT3,inhibitor of STAT3 signalingbardoxolone methyl,,electrophilic inducer of the NFE2L2-KEAP1 pathwayhyperforin,TRPC6,agonist of calcium-permeable ion channelsBRD4132,,screening hitregorafenib,BRAF;KDR;KIT;RET,"inhibitor of BRAF, RET, KIT, and VEGFR2"sorafenib,BRAF;FLT3;KDR;RAF1,"inhibitor of BRAF, CRAF, and VEGFR2"BRD-K51490254,HDAC6;HDAC8,inhibitor of HDAC6 and HDAC8EX-527,SIRT1,inhibitor of sirtuin 1bendamustine,,DNA alkylatorPYR-41,UBA1,inhibitor of ubiquitin-activating enzyme in cellsB02,RAD51,inhibitor of RAD51ML031,S1PR2,inhibitor of sphingosine 1-phosphate receptor 2tipifarnib-P1,FNTA,inhibitor of farnesyltransferaseBRD9876,,screening hitparthenolide,,natural product; modulator of ROS; modulator of NF-kappa-B signalingtandutinib,FLT3;KIT,inhibitor of c-KIT and VEGFR3CID-5951923,KLF5,modulator of KLF5 expressionDBeQ,VCP,inhibitor of p97 in cellsLE-135,RARB,antagonist of retinoic acid receptor betaBRD-K24690302,HDAC1,inhibitor of HDAC1ML203,PKM,activator of muscle pyruvate kinase (PKM2)dexamethasone,NR3C1,agonist of glucocorticoid receptorBRD8899,STK33,inhibitor of serine/threonine kinasase STK33KH-CB19,CLK1;CLK4,inhibitor of CDC2-like kinases 1 and 4MK-0752,APH1A;NCSTN;PSEN1;PSENEN,inhibitor of gamma-secretaseSB-431542,TGFBR1,inhibitor of the transforming growth factor beta type 1 receptorRepligen 136,HDAC3,inhibitor of HDAC3OSI-930,KDR;KIT,inhibitor of c-KIT and VEGFR2tacrolimus,PPP3CA;PPP3CB;PPP3CC;PPP3R1;PPP3R2,inhibitor of calcineurincytarabine hydrochloride,,inducer of DNA damageclofarabine,,inducer of DNA damage3-Cl-AHPC,NR0B2,binder of nuclear receptor SHPCD-437,RARG,agonist of retinoic acid receptor gammagemcitabine,CMPK1;RRM1;TYMS,"inhibitor of DNA replication; inhibitor of ribonucleotide reductase, thymidylate synthetase, and cytidine monophosphate (UMP-CMP) kinase"mitomycin,,DNA crosslinkerPF-184,IKBKB,inhibitor of IKK-2chlorambucil,,DNA alkylatorSN-38,TOP1,metabolite of irinotecan; inhibitor of topoisomerase Itopotecan,TOP1,inhibitor of topoisomerase Iindisulam,CA9,inhibitor of carbonic anhydrase isoform IXbarasertib,AURKB,inhibitor of aurora kinase Balisertib,AURKA;AURKB,inhibitor of aurora kinases A and Bbleomycin A2,,inducer of DNA damagedoxorubicin,TOP2A,inhibitor of topoisomerase IIteniposide,TOP2A;TOP2B,inhibitor of topoisomerase IIetoposide,TOP2A,inhibitor of topoisomerase IIruxolitinib,JAK1;JAK2,inhibitor of Janus kinases 1 and 2RAF265,BRAF;KDR,ihibitor of VEGFR2 and BRAFpyrazolanthrone,MAPK10;MAPK8;MAPK9,inhibitor of Jun N-terminal kinase (JNK) 1/2/3TPCA-1,IKBKB,inhibitor of IKK-2AZ-3146,TTK,inhibitor of TTK protein kinaseMdivi-1,DNM1,inhibitor of dynamin 1; inhibitor of mitrochondrial division inhibitorelocalcitol,VDR,agonist of vitamin D receptorSU11274,MET,inhibitor of METBRD1835,EZH2,product of diversity oriented synthesis; screening hitSID 26681509,CTSL1,inhibitor of cathepsin Lpevonedistat,NAE1,inhibitor of Nedd-8 activating enzymeBRD-K35604418,MCL1,inhibitor of MCL1ETP-46464,ATM;ATR,inhibitor of serine/threonine-protein kinase ATRNSC48300,TASP1,inhibitor of threonine endopeptidase taspase 1curcumin,,natural product; modulator of ROS; modulator of NF-kappa-B signalingsunitinib,FLT1;FLT3;KDR;KIT;PDGFRA;PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta"KW-2449,AURKA;FLT3,inhibitor of FLT3 and AURKAAZD4547,FGFR1;FGFR2;FGFR3,inhibitor of fibroblast growth factor receptorslenvatinib,FLT1;FLT3;KDR;KIT;PDGFRA;PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta"pazopanib,FLT1;FLT3;KDR;KIT;PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFRB"tivozanib,FLT1;FLT3;KDR,inhibitor of VEGFRsaxitinib,FLT1;FLT3;KDR;KIT;PDGFRA;PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta"Ki8751,KDR;KIT;PDGFRA,"inhibitor of VEGFR2, c-KIT, and PDGFRA"cediranib,FLT1;FLT4;KDR,inhibitor of VEGFRsMGCD-265,FLT1;FLT3;KDR;MET,inhibitor of c-MET and VEGFRsforetinib,KDR;MET,inhibitor of MET and VEGFR2cabozantinib,FLT3;KDR;MET;RET,"inhibitor of c-MET, VEGFR2/3, and RET"tamatinib,SYK,inhibitor of spleen tyrosine kinasenintedanib,FGFR1;FGFR2;FGFR3;FLT1;FLT3;KDR;PDGFRA;PDGFRB,"inhibitor of c-KIT, VEGFRs, PDGFRs, and FGFRs"PIK-93,PIK3CG,inhibitor of PI3K catalytic subunit gammaKU 0060648,PRKDC,inhibitor of DNA-dependent protein kinaseMK-2206,AKT1,inhibitor of AKT1GDC-0941,PIK3CA;PIK3CB;PIK3CD;PIK3CG,inhibitor of PI3K kinase activityZSTK474,PIK3CB;PIK3CD;PIK3CG,"inhibitor of PI3K catalytic subunits beta, delta, and gamma"GSK1059615,MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG,inhibitor of PI3K and mTOR kinase activityNVP-BEZ235,MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG,inhibitor of PI3K and mTOR kinase activityBYL-719,PIK3CA,inhibitor of PI3K catalytic subunit alphatemsirolimus,MTOR,inhibitor of mTORsirolimus,MTOR,inhibitor of mTOROSI-027,MTOR,inhibitor of mTORC1 and mTORC2KU-0063794,MTOR,inhibitor of mTORAZD8055,MTOR,inhibitor of mTORPF-573228,PTK2,inhibitor of focal adhesion kinasecrizotinib,ALK;MET,inhibitor of c-MET and ALKNVP-BSK805,JAK2,inhibitor of Janus kinase 2TG-101348,JAK2,inhibitor of Janus kinase 2AT7867,AKT1;AKT2;AKT3;RPS6KB2,inhibitor of AKT1/2/3 and S6Kcytochalasin B,,inhibitor of actin polymerizationNVP-TAE684,ALK,inhibitor of ALK and ALK-NPM fusion proteinBMS-754807,IGF1R,inhibitor of insulin-like growth factor 1 receptor and insulin receptorBMS-536924,IGF1R;INSR,inhibitor of insulin-like growth factor 1 receptor (IGF1R) and insulin receptor (INSR)linsitinib,IGF1R;INSR,inhibitor of insulin-like growth factor 1 receptor and insulin receptorNVP-ADW742,IGF1R,inhibitor of insulin-like growth factor 1 receptorcyanoquinoline 11,MAP3K8,inhibitor of MAP3K8; inhibitor of phosphorylated EGFR in cellsaustocystin D,,natural product; inducer of DNA damageolaparib,PARP1;PARP2,inhibitor of poly (ADP-ribose) polymerase 1 and 2PI-103,MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG;PRKDC,"inhibitor of DNA-PK, PI3K p110 delta, mTORC1, and catalytic subunits of PI3K"triptolide,,natural product; inhibitor of RNA polymerase IIcucurbitacin I,,natural product; modulator of NFKB1 and STAT3 signalingKPT185,XPO1,inhibitor of exportin 1NSC632839,USP13;USP5,inhibitor of ubiquitin isopeptidaseLRRK2-IN-1,DCLK1;LRRK2,inhibitor of leucine-rich repeat kinase 2; inhibitor of doublecortin-like kinaseJQ-1,BRDT,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteinsGSK525762A,BRD2;BRD3;BRD4,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteinsI-BET151,BRD2;BRD3;BRD4,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteinsnutlin-3,MDM2,inhibitor of p53-MDM2 interactionHLI 373,MDM2,inhibitor of MDM2serdemetan,MDM2,inhibitor of MDM2necrosulfonamide,,inhibitor of downstream signaling of RIP3 associated with MLKLHBX-41108,USP7,inhibitor of the deubiquitinase activity of USP7SMER-3,CUL1;SKP1,inhibitor of E3-ubiquitin ligaseBRD-K28456706,HNF4A,inhibitor of hepatocyte nuclear factor 4 alphaBRD-K45681478,,product of diversity oriented synthesis; screening hitmethylstat,KDM3A;KDM4A;KDM4B;KDM4C;KDM4D,inhibitor of lysine specific demethylasesPL-DI,,dimer of piperlongumine; inducer of ROSpiperlongumine,,natural product; modulator of ROS levelsBRD-K34222889,,analog of the natural product piperlonguminecerulenin,FASN;HMGCS1,inhibitor of fatty acid synthase; inhibitor of HMG-CoA synthaseBRD-K26531177,,analog of the natural product piperlongumineNSC95397,CDC25A;CDC25B;CDC25C,inhibitor of cell division cycle 25 phosphatase (CDC25)manumycin A,FNTA;FNTB,inhibitor of RAS farnesyltransferaseCCT036477,,inhibitor of WNT signaling by blocking beta-catenin transcriptionPX-12,TXN,inhibitor of thioredoxin-1PRIMA-1,TP53,re-activator of the pro-apoptotic activity of mutant p53968,GLS,inhibitor of glutaminaseML029,,inhibitor of antigen receptor-mediated NFkappaB activityAZD1480,JAK1;JAK2,inhibitor of Janus kinases 1 and 2RITA,MDM2;TP53,inhibitor of p53-MDM2 interactionABT-199,BCL2,inhibitor of BCL2ABT-737,BCL2;BCL2L1;BCL2L2,"inhibitor of BCL2, BCL-xL, and BCL-W"navitoclax,BCL2;BCL2L1;BCL2L2,"inhibitor of BCL2, BCL-xL, and BCL-W"R428,AXL,inhibitor of the tyrosine-protein kinase receptor UFONSC23766,RAC1;TIAM1;TRIO,inhibitor of RAC1-GEF interaction; prevents Rac1 activation by Rac-specific guanine nucleotide exchange factors (GEFs) TrioN and Tiam1BIX-01294,EHMT2,inhibitor of G9a histone methyltransferaseUNC0638,EHMT1;EHMT2,inhibitor of EHMT2 and GLP methyltransferasePF-543,SPHK1,inhibitor of sphingosine kinase-1prochlorperazine,DRD2,inhibitor of dopamine receptor D2trifluoperazine,DRD2,antagonist of dopamine receptor D2SCH-529074,TP53,activator of mutant p53fingolimod,S1PR1,inhibitor of sphingosine 1-phosphate receptorGW-405833,CNR2,partial agonist of cannabinoid receptor 2StemRegenin 1,AHR,inhibitor of aryl hydrocarbon receptorBax channel blocker,BAX,inhibitor of BAX-mediated mitochondrial cytochrome c releaseCompound 23 citrate,,analog of natural product cortistatinnilotinib,ABL1;BCR;KIT,"inhibitor of ABL1, BCR, and c-KIT"masitinib,KIT;PDGFRA;PDGFRB,"inhibitor of c-KIT, PDGFRA, and PDGFRB"imatinib,ABL1;BCR;KIT,inhibitor of BCR-ABL1 and c-KITGANT-61,,inhibitor of hedgehog signaling pathwayKU-55933,ATM,inhibitor of ataxia telangiectasia mutated (ATM)KU-60019,ATM,inhibitor of ataxia telangiectasia mutated (ATM)BRD-K11533227,HDAC1;HDAC2,inhibitor of HDAC1 and HDAC2neuronal differentiation inducer III,,induction of rat HCN cell differentiation as judged by induction of neuronal reporter neuroD activityBRD-K66532283,HDAC1;HDAC2,inhibitor of HDAC1 and HDAC2BRD-K80183349,HDAC1;HDAC2,inhibitor of HDAC1 and HDAC2tacedinaline,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8"LBH-589,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8"belinostat,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8"vorinostat,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8"apicidin,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8"ISOX,HDAC6,inhibitor of HDAC6entinostat,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8"Merck60,HDAC1;HDAC2,inhibitor of HDAC1 and HDAC2BRD-K61166597,,inhibitor of HDAC1 and HDAC2BRD-A86708339,,screening hitciclopirox,RRM1,substituted pyridone antimycotic; inhibitor of the iron-dependent enzyme ribonucleotide reductasePAC-1,CASP3,activator of procaspase-3obatoclax,BCL2;BCL2L1;MCL1,"inhibitor of MCL1, BCL2, and BCL-xL"BRD-K63431240,,product of diversity oriented synthesis; screening hitsotrastaurin,PRKCB,inhibitor of protein kinase C betaNSC19630,WRN,inhibitor of Werner syndrome helicase activityPDMP,UGCG,inhibitor of ceramide glucosyltransferasemarinopyrrole A,MCL1,natural product; putative inhibitor of MCL1bafilomycin A1,ATP6V0A1,inhibitor of the vacuolar-type H+-ATPaseBRD-K33514849,,screening hitBRD-K04800985,,product of diversity oriented synthesisBRD-K02251932,,product of diversity oriented synthesisBRD-K14844214,,product of diversity oriented synthesisistradefylline,ADORA2A,antagonist of the adenosine A2A receptorBIRB-796,MAPK11;MAPK11;MAPK14,inhibitor of p38 MAPKWAY-362450,NR1H4,agonist of farnesoid X receptorveliparib,PARP1;PARP2,inhibitor of poly (ADP-ribose) polymerase 1 (PARP1) and 2 (PARP2)BRD-K90370028,,screening hitthalidomide,CRBN,immunomodulatory drug; binder of cereblonSZ4TA2,BCL2L1,inhibitor of BCL-xLCBB-1007,KDM1A,inhibitor of lysine-specific demethylase 1A (LSD1)ML050,GPER1,antagonist of GPR30BMS-270394,RARG,antagonist of retinoic acid receptor gammaskepinone-L,MAPK14,inhibitor of p38 MAPKMI-2,MEN1,binder of menin; inhibitor of menin-MLL fusion proteinTG-100-115,PIK3CD;PIK3CG,inhibitor of PI3K catalytic subunits delta and gammaAZD6482,PIK3CB;PIK3CD,inhibitor of PI3K catalytic subunits beta and deltaTGX-221,PIK3CB,inhibitor of PI3K catalytic subunit betaCAL-101,PIK3CD,inhibitor of PI3K catalytic subunit deltapluripotin,MAPK1;RASAL1,promoter of embryonic stem cell self-renewal; inhibitor of Ras-GAP and ERKsaracatinib,ABL1;SRC,inhibitor of SRC and ABL1dasatinib,EPHA2;KIT;LCK;SRC;YES1,"inhibitor of SRC, YES1, EPHA2, c-KIT, and LCK"WZ4002,EGFR,inhibitor of EGFR targeting T790M resistancePD 153035,EGFR,inhibitor of EGFRibrutinib,BTK,inhibitor of Bruton's tyrosine kinaseWZ8040,EGFR,inhibitor of EGFR targeting T790M resistancebosutinib,ABL1;SRC,inhibitor of SRC and ABL1gefitinib,AKT1;EGFR,inhibitor of EGFR and AKT1erlotinib,EGFR;ERBB2,inhibitor of EGFR and HER2vandetanib,EGFR;KDR,inhibitor of VEGFR2 and EGFRcanertinib,EGFR;ERBB2,inhibitor of EGFR and HER2lapatinib,EGFR;ERBB2,inhibitor of EGFR and HER2afatinib,EGFR;ERBB2,inhibitor of EGFR and HER2neratinib,EGFR;ERBB2,inhibitor of EGFR and HER2BRD-K71935468,,inducer of ROSBRD-K94991378,,inducer of ROSVER-155008,HSPA1A;HSPA1B;HSPA1L,inhibitor of HSP70IPR-456,PLAUR,inhibitor of the interaction of urokinase receptor with binding partnersBRD9647,,screening hitC6-ceramide,MAPK1;PPP2CA;UGCG,inhibitor of glucosylceramide synthase; activator of MAP kinase (ERK); stimulator of protein phosphatase 2AVU0155056,PLD1;PLD2,inhibitor of phospholipase D1/D2Ko-143,ABCG2,inhibitor of breast cancer resistance protein multidrug transporter (BCRP)L-685458,APH1A;NCSTN;PSEN1;PSENEN,inhibitor of gamma-secretaseMI-1,MEN1,binder of menin; inhibitor of menin-MLL fusion proteinUNC0321,EHMT2,inhibitor of G9a histone methyltransferasefumonisin B1,CERS1;CERS2;CERS3;CERS4;CERS5;CERS6,inhibitor of ceramide synthaseGSK4112,NR1D1,antagonist of Rev-ErbAalphaciclosporin,PPID,inhibitor of calcineurin by binding to cyclophilin DHC-067047,TRPV4,inhibitor of cation channel TRPV4BRD-A71883111,IDH1,putative inhibitor of IDH1 R132Htretinoin,RARA;RARB;RARG,agonist of retinoid acid receptorsCh-55,RARA;RARB;RARG,agonist of retinoid acid receptorsBRD-K29086754,,product of diversity oriented synthesisAGK-2,SIRT2,inhibitor of sirtuin 2BRD-K33199242,,product of diversity oriented synthesisBRD-K19103580,,product of diversity oriented synthesisBRD-K41597374,,product of diversity oriented synthesisBRD-K09587429,,product of diversity oriented synthesisBRD-K52037352,,product of diversity oriented synthesisBRD-K27986637,,product of diversity oriented synthesis; screening hitBRD-K48334597,,product of diversity oriented synthesisRO4929097,APH1A;NCSTN;PSEN1;PSENEN,inhibitor of gamma-secretasetrametinib,MAP2K1;MAP2K2,inhibitor of MEK1 and MEK2PD318088,MAP2K1;MAP2K2,inhibitor of MEK1 and MEK2selumetinib,MAP2K1;MAP2K2,inhibitor of MEK1 and MEK2BRD-K51831558,EZH2,inhibitor of enhancer of zeste polycomb repressive complex 2 subunitJW-55,TNKS,inhibitor of tankyraseJW-74,,inhibitor of WNT signalingGSK2636771,PIK3CB,inhibitor of PI3K catalytic subunit betaPRIMA-1-Met,TP53,re-activator of the pro-apoptotic activity of mutant p53ML312,SCARB1,"inhibitor of scavenger receptor class B, member 1 (SCARB1)-mediated lipid uptake"BRD-K16147474,,product of diversity oriented synthesisetomoxir,CPT1A,inhibitor of carnitine palmitoyltransferaseBRD-K49290616,,product of diversity oriented synthesisFGIN-1-27,TSPO,activator of peripheral benzodiazepine receptor/translocator proteinBRD-K96431673,,product of diversity oriented synthesisBRD-K96970199,,product of diversity oriented synthesisBRD-K17060750,,product of diversity oriented synthesisBRD-K86535717,,product of diversity oriented synthesisBRD-K02492147,,product of diversity oriented synthesisBRD-K75293299,,product of diversity oriented synthesissitagliptin,DPP4,inhibitor of dipetidyl peptidase-4SGX-523,MET,inhibitor of METNSC30930,SRD5A2,inhibitor of steroid 5-alpha reductasequizartinib,FLT3,inhibtor of VEGFR3XL765,MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG;PRKDC,inhibitor of mTOR and PI3K kinase acitivitiesBRD-K85133207,HDAC1,inhibitor of HDAC116-beta-bromoandrosterone,,dehydroepiandrosterone (DHEA) analogtosedostat,ANPEP;LAP3;NPEPPS,"inhibitor of leucine aminopeptidase 3 (LAP), puromycin-sensitive aminopeptidase (PuSA), and aminopeptidase N"AT-406,XIAP,SMAC mimetic; inhibitor of inhibitor of apoptosis proteins (IAPs)birinapant,DIABLO;XIAP,SMAC mimetic; inhibitor of inhibitor of apoptosis proteins (IAPs)SRT-1720,SIRT1,activator of sirtuin-1epigallocatechin-3-monogallate,,natural productBRD-K13999467,,product of diversity oriented synthesisBRD-A94377914,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8"Compound 7d-cis,XPO1,inhibitor of CRM1-mediated nucleocytoplasmic transporttipifarnib-P2,FNTA,inhibitor of farnesyltransferasemyriocin,SPTLC1;SPTLC2;SPTLC3,inhibitor of serine palmitoyltransferaseavrainvillamide,NPM1,natural product; inhibitor of nucleophosminAC55649,RARB,agonist of retinoic acid receptor betalomeguatrib,MGMT,inhibitor of methylguanine-DNA methyltransferasesemagacestat,APH1A;NCSTN;PSEN1;PSENEN,inhibitor of gamma-secretaseSR1001,RORA;RORC,synthetic ROR ligand; suppressor of TH17 differentiationBMS-195614,RARA;RARB;RARG,antagonist of retinoic acid receptorsvorapaxar,F2R,antagonist of proteinase-activated receptor 1 (PAR1)blebbistatin,MYH1;MYH2,inhibitor of myosin II ATPasesFSC231,PICK1,inhibitor of PDZ domain of protein interacting with PRKCA 1 (PICK1)ML258,BCL2L10,inhibitor of BIM-BCL-B interactionO-6-benzylguanine,MGMT,inhibitor of O(6)-alkylguanine DNA alkyltransferasesCompound 1541A,CASP3;CASP6;CASP7,"activators of executioner procaspases 3, 6, and 7"tubastatin A,HDAC6,inhibitor of tubulin deacetylase activity of HDAC6CIL55,,screening hitCAY10576,IKBKE,inhibitor of IKK-epsilonBRD-K41334119,,product of diversity oriented synthesisBRD-K27224038,,product of diversity oriented synthesisBRD-K84807411,,product of diversity oriented synthesisBRD-K30019337,,product of diversity oriented synthesisBRD-K78574327,,product of diversity oriented synthesisBRD-K42260513,EZH2,inhibitor of enhancer of zeste polycomb repressive complex 2 subunitIU1,USP14,inhibitor of the deubiquitinase activity of USP14LY-2157299,TGFBR1,inhibitor of the transforming growth factor beta type 1 receptorBCL-LZH-4,,"inhibitor of BCL2, BCL-xL, and MCL1"PF-4800567 hydrochloride,CSNK1D;CSNK1E,inhibitor of casein kinase isoforms delta and epsilonpandacostat,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8"BRD6340,,screening hitBEC,ARG1;ARG2,inhibitor of arginase I and IIVAF-347,AHR,inhibitor of aryl hydrocarbon receptorBRD-K34485477,,product of diversity oriented synthesisBRD-K37390332,,product of diversity oriented synthesisBRD-K44224150,,product of diversity oriented synthesisprocarbazine,,inducer of DNA damagenecrostatin-1,RIPK1,inhibitor of receptor-interacting protein kinase 1; inhibitor of the necroptosis cell death pathwaysildenafil,PDE5A,inhibitor of phosphodiesterase 5Acyclophosphamide,,DNA alkylatorML083,PKM,activator of muscle pyruvate kinasenecrostatin-7,,inhibitor of necroptosisbexarotene,RXRA;RXRB;RXRG,inhibitor of retinoid X receptorsSCH-79797,F2R,antagonist of proteinase-activated receptor 1 (PAR1)methotrexate,DHFR,inhibitor of dihydrofolate reductaseRG-108,DNMT1,inhibitor of DNA methyltransferaseGMX-1778,NAMPT,inhibitor of nicotinamide phosphoribosyltransferaseSTF-31,NAMPT,inhibitor of nicotinamide phosphoribosyltransferasedaporinad,NAMPT,inhibitor of nicotinamide phosphoribosyltransferaseCAY10618,NAMPT,inhibitor of nicotinamide phosphoribosyltransferasedacarbazine,,DNA alkylatorfluorouracil,TYMS,pyrimidine analog; inhibitor of thymidylate synthasedecitabine,DNMT1,inhibitor of DNA methyltransferasePF-3758309,PAK4,inhibitor of serine/threonine p21-activating kinase 4omacetaxine mepesuccinate,,inhibitor of protein translation by preventing protein elongationSNS-032,CDK16;CDK17;CDK2;CDK7;CDK9;CDKL5,inhibitor of cyclin-dependent kinasesPHA-793887,CDK1;CDK2;CDK4;CDK5;CDK7;CDK9,inhibitor of cyclin-dependent kinasesleptomycin B,XPO1,inhibitor of exportin 1narciclasine,RHOA,activates cellular activity of RhoA; modulator of Rho/Rho kinase/LIM kinase/cofilin signalingSR-II-138A,EIF4A2;EIF4E;EIF4G1,silvestrol analog; inhibits translation by modulating the eIF4F complexCR-1-31B,EIF4A2;EIF4E;EIF4G1,silvestrol analog; inhibits translation by modulating the eIF4F complexBMS-345541,IKBKB,inhibitor of IKK-2dinaciclib,CDK1;CDK2;CDK5;CDK9,inhibitor of cyclin-dependent kinasesalvocidib,CDK1;CDK2;CDK4;CDK6,inhibitor of cyclin-dependent kinaseslinifanib,FLT1;FLT3;KDR,inhibitor of VEGFRsMK-1775,WEE1,inhibitor of WEE1AZD7762,CHEK1;CHEK2,inhibitor of checkpoint kinases 1 and 2N9-isopropylolomoucine,CCNB1;CDK1;CDK5;CDK5R1,inhibitor of CDK1/cyclin B and CDK5/p35 complexesmomelotinib,JAK1;JAK2,inhibitor of Janus kinases 1 and 2AT13387,HSP90AA1,inhibitor of HSP90SNX-2112,HSP90AA1;HSP90B1,inhibitor of HSP90alpha and HSP90betatanespimycin,HSP90AA1,inhibitor of HSP90NVP-231,CERK,inhibitor of ceramide kinaseML311,MCL1,inhibitor of MCL1GW-843682X,PLK1;PLK3,inhibitor of PLK1 and PLK3LY-2183240,FAAH,inhibitor of fatty acid amide hydrolase; inhibitor of anandamide uptakeBI-2536,PLK1,inhibitor of polo-like kinase 1 (PLK1)GSK461364,PLK1,inhibitor of polo-like kinase 1 (PLK1)triazolothiadiazine,PDE4A;PDE4B;PDE4D,inhibitor of phosphdiesterase 4A/B/Dvincristine,,inhibitor of mictrotubule assemblyparbendazole,,inhibitor of microtubule assemblyKX2-391,SRC,peptide mimetic; inhibitor of SRC activity in cellspaclitaxel,,inhibitor of microtubule assemblySB-743921,KIF11,inhibitor of kinesin 11rigosertib,PIK3CA;PIK3CB;PLK1,inhibitor of polo-like kinase 1; inhibitor of PI3K catalytic subunits alpha and betaBRD-K70511574,PLK1,inhibitor of polo-like kinase 1 (PLK1)ceranib-2,ACER1;ACER2;ACER3;ASAH1;ASAH2;ASAH2B,inhibitor of ceramidase activitynakiterpiosin,,natural product; inhibitor of microtubule assemblyBRD-K66453893,,product of diversity oriented synthesisSB-225002,CXCR2,inhibitor of chemokine receptor 2CHM-1,,inhibitor of tubulin polymerizationFQI-1,,inhibitor of LSF1-mediated transcriptionFQI-2,,inhibitor of LSF1-mediated transcriptionELCPK,,screening hitdocetaxel,,inhibitor of microtubule assemblytivantinib,MET,inhibitor of MET; inhibitor of microtubule assemblyYK 4-279,DHX9;ERG;ETV1,inhibitor of RNA helicase A (RHA) binding to EWS-FLI1; inhibitor of ERG and ETV1 activityisoevodiamine,,natural productbrefeldin A,ARF1,modulator of ADP-ribosylation factor 1; inhibitor of protein translocation from ER to Golgiouabain,ATP1A1;ATP1A2;ATP1A3;ATP1A4;ATP1B1;ATP1B2;ATP1B3;ATP1B4,cardiac glycoside; inhibitor of the Na+/K+-ATPaseBRD-K30748066,CDK9,inhibitor of CDK9CIL55A,,screening hitMG-132,PSMB1;PSMB2;PSMB5;PSMD1;PSMD2,inhibitor of the proteosomeMLN2238,PSMB5,inhibitor of 20S proteasome at the chymotrypsin-like proteolytic (beta-5) sitebortezomib,PSMB1;PSMB2;PSMB5;PSMD1;PSMD2,inhibitor of 26S proteasomepalmostatin B,LYPLA1,inhibitor of acyl-protein thioesterase 1pitstop2,CLTA;CLTB;CLTC;CLTCL1,inhibitor of clathrin and clathrin-independent endocytosisdarinaparsin,,inducer of ROS; inhibitor of microtubule assemblyQW-BI-011,EHMT2,inhibitor of G9a histone methyltransferaseSJ-172550,MDM2;TP53,inhibitor of p53-MDM2 interactionIC-87114,PIK3CD,inhibitor of PI3K catalytic subunit deltaBRD-K50799972,,product of diversity oriented synthesisBRD-K55116708,,product of diversity oriented synthesis; inhibitor of leukemic stem cellsfluvastatin,HMGCR,inhibitor of HMG-CoA reductaselovastatin,HMGCR,inhibitor of HMG-CoA reductasesimvastatin,HMGCR,inhibitor of HMG-CoA reductasestaurosporine,,inhibitor of multiple kinasesGSK-3 inhibitor IX,,inhibitor of JAK/STAT signalingCHIR-99021,GSK3B,inhibitor of GSK3 betaavicin D,,natural productCIL56,,screening hiterastin,SLC7A11;VDAC1;VDAC2,modulator of voltage-dependent anion channels; inhibitor of solute carrier SLC7A11ML210,,selectively kills engineered cells expressing mutant HRASML162,,selectively kills engineered cells expressing mutant HRAS"1S,3R-RSL-3",GPX4,synthetic lethal with HRAS in engineered cells; inhibitor of GPX4CIL41,,screening hitCIL70,,screening hitBRD-K01737880,,screening hitVX-680,AURKA;AURKB;AURKC,inhibitor of aurora kinasesisoliquiritigenin,,natural producttigecycline,,analog of tetracyclineCOL-3,,analog of tetracyclineBRD-K71781559,,screening hitMLN2480,ARAF;BRAF;RAF1,inhibitor of RAF kinasesGDC-0879,BRAF,inhibitor of BRAFdabrafenib,BRAF,inhibitor of BRAFPLX-4720,BRAF,inhibitor of BRAFML320,GSK3B,inhibitor of GSK3 betaBRD-K29313308,HDAC3,inhibitor of HDAC3BRD-K88742110,HDAC8,inhibitor of HDAC8BRD-A02303741,DOT1L,inhibitor of histone methyltransferasesNSC 74859,STAT3,inhibitor of STAT3AZD7545,PDK2,inhibitor of pyruvate dehydrogenase kinase 2PLX-4032,BRAF,inhibitor of BRAFcompound 1B,,screening hitBRD-K99006945,,screening hitfulvestrant,ESR1;GPER1,antagonist of the estrogen receptorSKI-II,SPHK1,inhibitor of sphingosine kinase 1cimetidine,HRH2,inhibitor of histidine receptor H2JW-480,NCEH1,inhibitor of serine hydrolase enzyme NCEHitraconazole,,anti-fungal agent; inhibitor of hedgehog signaling pathwaypifithrin-mu,HSPA1A;HSPA1B;HSPA1L;TP53,inhibitor of p53 binding to mitochondria; inhibitor of HSP70SB-525334,TGFBR1,inhibitor of the transforming growth factor beta type 1 receptorphloretin,SLC5A1,natural product; inhibitor of glucose uptakevaldecoxib,PTGS2,inhibitor of cyclooxygenase-2 (COX2)PF-750,FAAH,inhibitor of fatty acid amide hydrolaseML239,,ML239; inhibitor of breast cancer stem cell proliferationMST-312,TERT,inhibitor of telomerase reverse transcriptaseTW-37,BCL2;BCL2L1,inhibitor of BCL2 and BCL-xLgossypol,BCL2;BCL2L1;LDHA;LDHB;LDHC,inhibitor of lactate dehydrogenase; inhibitor of BCL2 family membersBRD1812,,screening hitYM-155,BIRC5,inhibitor of survivin expressionBRD-K92856060,,screening hitneopeltolide,,inhibitor of cellular respirationKHS101,TACC3,"binder of TACC3, a component of the centrosome and mitotic spindle"spautin-1,USP10;USP13,inhibitor of the deubiquitinase activity of USP13 and USP10oligomycin A,ATP5L2,inhibitor of mitochondrial ATP synthaseBRD-K97651142,,aphrocallistin derivativeSR8278,NR1D1,antagonist of Rev-ErbAalphaGSK-J4,KDM6A;KDM6B,inhibitor of lysine-specific demethylases